Skip header and navigation

Refine By

2 records – page 1 of 1.

Concordance in judgments among c-erbB-2 (HER2/neu) overexpression detected by two immunohistochemical tests and gene amplification detected by Southern blot hybridization in breast carcinoma.

https://arctichealth.org/en/permalink/ahliterature20067
Source
Pathol Int. 2001 Jan;51(1):26-32
Publication Type
Article
Date
Jan-2001
Author
H. Tsuda
Y. Tani
T. Hasegawa
T. Fukutomi
Author Affiliation
Pathology Division, National Cancer Center Research Institute and Hospital, Tokyo, Japan. htsuda@cc.ndmc.ac.jp
Source
Pathol Int. 2001 Jan;51(1):26-32
Date
Jan-2001
Language
English
Publication Type
Article
Keywords
Blotting, Southern
Breast Neoplasms - genetics - metabolism - mortality - pathology - surgery
Carcinoma - genetics - metabolism - mortality - secondary - surgery
Comparative Study
DNA, Neoplasm - analysis
Female
Humans
Immunohistochemistry - methods
Middle Aged
Neoplasm Staging
Observer Variation
Reagent kits, diagnostic
Receptor, erbB-2 - metabolism
Receptors, Estrogen - metabolism
Receptors, Progesterone - metabolism
Reproducibility of Results
Research Support, Non-U.S. Gov't
Survival Rate
Abstract
We compared the c-erbB-2 protein overexpression status detected by the HercepTestTM (DAKO A/S, Grostrup, Denmark) with another conventional immunohistochemistry system using an anti-c-erbB-2 rabbit polyclonal antibody (Nichirei Co., Tokyo, Japan) and with the c-erbB-2 gene amplification status detected by Southern blot hybridization in 101 surgically resected breast carcinomas. According to the criteria for overexpression, recommended by the manufacturer, c-erbB-2 overexpression by HercepTestTM was detected in 24 cancers (24%), comprising six score-2 tumors and 18 score-3 tumors. The level of agreement in judgment of the HercepTestTM, among three independent observers, was excellent (kappa = 0.845). C-erbB-2 overexpression by Nichirei's antibody and c-erbB-2 gene amplification were detected in 21% and 16% of cases, respectively, and their concordance with HercepTestTM scores of 2-3 was 89% and 90%, respectively. In the score-3 cases by Hercep TestTM only, the concordance rates with overexpression by Nichirei's immunohistochemistry and with gene amplification were slightly higher, 94% and 93%, respectively. Score-2 cases by HercepTestTM were mostly judged as negative overexpression by Nichirei's antibody and as no amplification by Southern blot hybridization. The present results showed that HercepTestTM score-3 detected c-erbB-2 overexpression almost optimally as well as the conventional methods and the score-3 breast carcinomas had clinical and biological implications. Further examination would be necessary to decide the significance of breast cancers of HercepTestTM score 2.
PubMed ID
11148460 View in PubMed
Less detail

Quantitative immunohistochemical evaluation of HER2/neu expression with HercepTestTM in breast carcinoma by image analysis.

https://arctichealth.org/en/permalink/ahliterature20066
Source
Pathol Int. 2001 Jan;51(1):33-6
Publication Type
Article
Date
Jan-2001
Author
Y. Hatanaka
K. Hashizume
Y. Kamihara
H. Itoh
H. Tsuda
R Y Osamura
Y. Tani
Author Affiliation
Department of Immunohistochemistry, DAKO Japan Co. Ltd, 18 Kakkyoyama, Nishinitoin-higashiru, Shijo-dori, Simogyo, Kyoto 600-8493, Japan.
Source
Pathol Int. 2001 Jan;51(1):33-6
Date
Jan-2001
Language
English
Publication Type
Article
Keywords
Adult
Aged
Aged, 80 and over
Breast Neoplasms - chemistry - pathology
Carcinoma, Ductal, Breast - chemistry - pathology
Comparative Study
Female
Humans
Image Processing, Computer-Assisted - methods
Immunohistochemistry - methods
Middle Aged
Observer Variation
Reagent kits, diagnostic
Receptor, erbB-2 - analysis
Reproducibility of Results
Abstract
HercepTestTM (DAKO A/S, Glostrup, Denmark) is an immunohistochemical assay that detects HER2/neu gene products, and evaluates the overexpression status of the HER2/neu protein in determining eligibility for the Trastuzumab (HerceptinR, Genentech, San Francisco, CA, USA) therapy. However, practically, interobserver variability of the HER2/neu interpretation of the immunostained results has caused marked disagreement with regard to the intensity of tumor staining. In this study, we quantitated HER2/neu expression by image analysis, and applied this analyzing system to help to minimize interobserver variability of the interpretation of the HercepTestTM. All the immunostained results were scored semiquantitatively on a range of 0 to 3+ in accordance with the criteria described as per the manufacturer's instructions, and quantitatively evaluated using an image analyzing system with image processing software. Among the 92 cases, 15 were scored as 3+, six were 2+, and 32 were 1+ under intraobservers agreement. When the cases were quantitated, a high correlation was shown between the signal area extracted by image analysis and the corresponding score of staining intensity with the HercepTestTM. By converting the quantitatively extracted data into a scoring system based upon the criteria, the outcome demonstrated a strong concordance with the scoring data obtained from immunostaining. The results indicated that a quantitative scoring system performed by simple image analysis may provide to improve interobserver agreement of the interpretation of the HercepTest TM in clinical practice.
PubMed ID
11148461 View in PubMed
Less detail